Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry

Journal of the National Cancer Institute

Volumn 88, Issue 20, 1996, Pages 1483-1488

  Sievers, Eric L ^f   Lange, Beverly J ^a   Buckley, Jonathan D ^b   Smith, Franklin O ^c   Wells, Denise A ^d   Daigneault Creech, Celeste A ^d   Shults, Keith E ^e   Bernstein, Irwin D ^g   Loken, Michael R ^d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c INDIANA UNIVERSITY   (United States)

^d HEMATOLOGICS INC   (United States)

^e Cytometry Associates Inc   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MORTALITY;

ACUTE DISEASE; ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, MYELOID; MALE; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK;

EID: 0029847342     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.20.1483     Document Type: Article

References (17)

1. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction [see comment citation in Medline]. Lancet 1994;343:196-200.
2. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993;82:1689-94.
3. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994;8:735-9.
4. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993;82:712-5.
5. Terstappen LW, Safford M, Loken MR. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia 1990;4: 657-63.
6. Terstappen LW, Loken MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990; 2:229-40.
7. Terstappen LW, Safford M, Konemann S, Loken MR, Zurlutter K, Buchner T, et al. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis [corrected and republished article originally printed in Leukemia 1991; 5:757-67]. Leukemia 1992;6:70-80.
8. Terstappen LW, Safford M, Unterhalt M, Konemann S, Zurlutter K, Piechotka K, et al. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 1992;6:993-1000.
9. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW, et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993;81: 3083-90.
10. Stelzer GT, Shults KE, Wormsley SB, Loken MR, Detection of occult lymphoma cells in bone marrow aspirates by multi-dimensional flow cytometry. Prog Clin Biol Res 1992;377:629-35.
11. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993;100:534-40.
12. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-220.
13. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 [see comment citation in Medline]. Blood 1992;80:2210-4.
14. Mayer RJ. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol 1987;14:384-96.
15. Mayer R, Davis R, Schiffer C, Berg D, Powell B, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
16. Wells RJ, Woods WG, Lampkin BC, Nesbit ME, Lee JW, Buckley JD, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol 1993;11:538-45.
17. Woods WG, Kobrinsky N, Buckley J, Neudorf S, Sanders J, Miller L, et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study [see comment citation in Medline]. J Clin Oncol 1993;11:1448-57.